Study of Palliative Radiation Combined with Pembrolizumab in Unresectable Metastatic Stage IV Breast Cancer

This is a phase 2, open-label, single-arm trial designed to evaluate the efficacy and safety of stereotactic body radiation therapy (SBRT) in combination with pembrolizumab following disease progression after two prior lines of standard therapy in unresectable metastatic stage IV breast cancer

Trial Details

NCT ID

NCT04990921

Phase

PHASE2

Sponsor

University of Louisville

Status

RECRUITING

Cancer Type

Breast Cancer

Interventions

Palliative Radiation and Pembrolizumab

Locations (sample)

Louisville, Kentucky, United States|38.25424,-85.75941

Key Eligibility Criteria

1\. Subject has provided informed consent/assent prior to initiation of any study specific activities/procedures.
2\. Female age ≥ 18 years at the time of informed consent. 3. Histologically confirmed diagnosis of breast cancer. 4. Disease stage: unresectable o…
7\. If subject received major surgery, must have recovered adequately from toxicity and/or complications from the intervention prior to enrollment.
8\. Subject must have received two prior lines of therapy and include a taxane in the adjuvant/neoadjuvant or metastatic setting.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →